3MB-PP1

CAT:
804-HY-102069-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
3MB-PP1 - image 1

3MB-PP1

  • Description :

    3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8) . 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM) . 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division[1][2][3].
  • UNSPSC :

    12352005
  • Hazard Statement :

    H302, H315, H319
  • Target :

    CDK; DAPK; Polo-like Kinase (PLK)
  • Type :

    Reference compound
  • Related Pathways :

    Apoptosis; Cell Cycle/DNA Damage
  • Applications :

    Cancer-Kinase/protease
  • Field of Research :

    Others
  • Assay Protocol :

    https://www.medchemexpress.com/3mb-pp1.html
  • Concentration :

    10mM
  • Purity :

    99.66
  • Solubility :

    DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
  • Smiles :

    NC1=C2C(N(C(C)(C)C)N=C2CC3=CC=CC(C)=C3)=NC=N1
  • Molecular Formula :

    C17H21N5
  • Molecular Weight :

    295.38
  • Precautions :

    H302, H315, H319
  • References & Citations :

    [1]Burkard ME, et al. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. ACS Chem Biol. 2012 Jun 15;7 (6) :978-81.|[2]Hollomon JM, et al. The Candida albicans Cdk8-dependent phosphoproteome reveals repression of hyphal growth through a Flo8-dependent pathway. PLoS Genet. 2022;18 (1) :e1009622. Published 2022 Jan 4.|[3]Al-Ghabkari A, et al. Validation of chemical genetics for the study of zipper-interacting protein kinase signaling. Proteins. 2018 Nov;86 (11) :1211-1217.
  • Shipping Conditions :

    Room Temperature
  • Storage Conditions :

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category :

    Reference compound1
  • Clinical Information :

    No Development Reported
  • CAS Number :

    [956025-83-5]